Rarely mentioned: how we arrived at the quantitative definition of a rare disease.
Level 5 - mechanism / opinion, no new human data
Narrative historical review and commentary (by design analogy, not clinical CEBM)
PubMed 35754591 · doi:10.1080/08998280.2022.2048613
What was done
This historical narrative investigated the policy origins and advocacy efforts that led to the Orphan Drug Act (ODA) of 1983 and its subsequent 1984 Amendments. The authors examined the historical background and informal negotiations among patient advocates, the Food and Drug Administration, academic researchers, and pharmaceutical executives that established the specific numerical threshold for defining a rare disease in the United States.
What was found
The original 1983 ODA defined rare diseases qualitatively, but the 1984 Amendments introduced a quantitative threshold of fewer than 200,000 affected individuals in the United States. Historical tracking revealed that this specific numerical cutoff was brokered informally during a conference break by two women representing key stakeholder interests. The review also notes that globally, an estimated 5,000 to 7,000 distinct rare diseases exist, collectively affecting over 300 million people worldwide (abstract reports "over 300,000 million"). No clinical or empirical datasets were analyzed.
Why it matters
It provides historical context on how regulatory definitions and market incentives for orphan drug development were established through grassroots patient advocacy rather than epidemiological modeling.
Limits
This is a narrative historical commentary rather than an empirical or systematic study. It relies on anecdotal historical documentation and does not evaluate clinical outcomes, economic impacts, or drug approval rates under the Orphan Drug Act.
Cited by
- supports In the United States, orphan diseases are defined as disorders affecting 200,000 people or fewer.